Ovarian Cancer Drug Market Set to More Than Double by 2022, Analysts Find
Bevacizumab and seven new therapies will drive market growth (December 11)
Decision Resources, a research and advisory firm for pharmaceutical and health care issues, finds that bevacizumab (Avastin, Roche/Genentech) will penetrate nearly all segments of the ovarian cancer market through 2022, driving the growth of the angiogenesis inhibitor drug class and contributing to an annual growth of approximately 10% in the overall ovarian cancer market.
In addition, the launch of three new angiogenesis inhibitors — trebananib (Amgen), nintedanib (Boehringer Ingelheim), and pazopanib (Votrient, GlaxoSmithKline) — will contribute to sales within this drug class, which is set to continue to dominate the treatment of ovarian cancer, accounting for 58% of total sales in 2022.
The report also expects products from three new drug classes to enter the ovarian cancer marketplace: the folate receptor-targeting small-molecule drug conjugate vintafolide (Merck); the poly (ADP-ribose) polymerase inhibitors olaparib (AstraZeneca) and niraparib (Tesaro); and the MEK inhibitor MEK162 (Array BioPharma/Novartis).
Experts interviewed for the report indicated that with the anticipated availability of numerous targeted agents in the treatment of ovarian cancer, determining the optimal sequencing of chemotherapy and targeted treatment options for patients progressing through numerous lines of therapy will become increasingly important.
“The ovarian cancer market is set to become crowded with targeted agents — in particular, with therapies targeting angiogenesis,” said senior analyst Gemma McConnell, PhD. “Emerging therapies in this drug class will face strong competition from the currently available therapy, Avastin, as well as from each other. Therefore, it will become increasingly important for agents to distinguish themselves from each other.”
Source: Decision Resources; December 11, 2013.